NasdaqGS - Delayed Quote USD

Replimune Group, Inc. (REPL)

6.42 +0.27 (+4.39%)
At close: April 26 at 4:00 PM EDT
6.42 0.00 (0.00%)
After hours: April 26 at 4:02 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Philip Astley-Sparke F.S.A. Executive Chairman 1.07M -- 1971
Dr. Sushil Patel Ph.D. Chief Executive Officer 665.05k -- 1971
Dr. Robert Coffin Ph.D. Founder, Chief Scientist & Director 785.89k -- 1965
Ms. Emily Luisa Hill Chief Financial Officer -- -- 1980
Mr. Andrew Schwendenman Chief Accounting Officer & Treasurer -- -- 1976
Mr. Christopher Sarchi Chief Commercial Officer -- -- 1968
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. Chief Medical Officer -- -- 1966
Mr. Paul Bullock Chief Manufacturing Officer & Framingham Site Head -- -- --

Replimune Group, Inc.

500 Unicorn Park Drive
Suite 303
Woburn, MA 01801
United States
781 222 9600 https://www.replimune.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
284

Description

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Corporate Governance

Replimune Group, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 16, 2024 - May 20, 2024
Replimune Group, Inc. Earnings Call

Related Tickers

YMAB Y-mAbs Therapeutics, Inc.
14.71
-0.88%
 
SRRK Scholar Rock Holding Corporation
14.53
+4.08%
 
ENTA Enanta Pharmaceuticals, Inc.
12.37
-0.88%
 
STRO Sutro Biopharma, Inc.
3.4200
0.00%
 
STOK Stoke Therapeutics, Inc.
12.41
+6.16%
 
BDTX Black Diamond Therapeutics, Inc.
5.89
+15.26%
 
PTGX Protagonist Therapeutics, Inc.
25.15
+1.99%
 
AURA Aura Biosciences, Inc.
7.22
+1.98%
 
RLAY Relay Therapeutics, Inc.
6.37
+3.49%
 
KYMR Kymera Therapeutics, Inc.
33.37
+0.06%